Roche

Revenues of the pharmaceutical division grew by 3.6%, driven by the immunology ($13.95bn) and oncology ($10.69bn) portfolio. Some of the new prescription drugs approved during the year included BALVERSA™ (erdafitinib), XARELTO® (rivaroxaban), SPRAVATO® (esketamine), INVOKANA® (canagliflozin) and STELARA® (ustekinumab).

J&J expects minor disruption to its pharmaceutical business in 2020 although growth is projected to remain above market growth. The majority of the categories of the consumer health segment are anticipated to perform well, although certain categories may be impacted due to reduced store visits and social distancing behaviours.

J&J is working towards the development of a COVID-19 vaccine through the Ad26® vector technology and PER.C6® manufacturing platform.